Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid
 somatropin formulation in children with growth hormone deficiency.
Inclusion Criteria:

 -  Written Informed Consent by patient and/or guardian/parents

 -  Patients with one of the following diagnosis: Growth failure due to growth hormone
 deficiency (GHD), Turner syndrome, or growth retardation in children with chronic
 renal disorders

 -  Patients who are willing to inject themselves and answer questionnaires or young
 patients whose parents/guardian are willing to inject their child and answer
 questionnaires

 -  Patients on growth hormone therapy for at least 6 weeks before entering the trial

 Exclusion Criteria:

 -  Pregnancy or breast feeding women

 -  Suspected or known allergy to trial product

 -  Other daily injection therapy (non-growth hormone, e.g insulin-therapy)

 -  Participating in any other trial involving other investigational products within the
 last 3 months